Search research articles

Search research articles

Related Experiment Videos

Vasoactive therapies in systemic sclerosis.

G Riemekasten¹, C Sunderkötter

¹MD. Department of Rheumatology and Clinical Immunology, Charité University Hospital, Schumannstr. 20/21, D-10117 Berlin, Germany. gabriela.riemekasten@charite.de

Rheumatology (Oxford, England)

|September 22, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dermatologie (Heidelberg, Germany)·2025

Same author

Dermatologie (Heidelberg, Germany)·2025

Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Same author

Therapy satisfaction and health literacy are key factors to improve medication adherence in systemic sclerosis.

Scandinavian journal of rheumatology·2022

Same author

[The unusual mimicker of a polymyositis].

Zeitschrift fur Rheumatologie·2022

Same author

[Progressive sclerodactyly in a Gambian farmer].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Systemic sclerosis (SSc) involves vasculopathy, leading to complications. This review details evidence-based vasoactive therapies, including prostacyclins and endothelin receptor antagonists, for managing SSc vasculopathy.

Area of Science:

Rheumatology
Vascular Medicine
Pharmacology

Background:

Systemic sclerosis (SSc) is characterized by central vasculopathy, a primary event causing complications like Raynaud's phenomenon, ulcers, and life-threatening pulmonary hypertension.
Vasoactive therapies are crucial for managing SSc patients, but treatment efficacy is often limited by study heterogeneity, small patient numbers, and short treatment durations.
Autoimmunity and other pathogenic mechanisms may further complicate SSc treatment, necessitating a multifaceted therapeutic approach.

Purpose of the Study:

To review evidence-based therapy recommendations for managing vasculopathy in systemic sclerosis.
To explore the potential disease-modifying capacity of emerging drugs on fibrosis, inflammation, and endothelial cells in SSc.
To provide a comprehensive overview of current therapeutic strategies for SSc-related vasculopathy.

Related Experiment Videos

Main Methods:

Literature review of studies on vasoactive therapies for systemic sclerosis.
Analysis of drug classes including prostacyclins, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.
Evaluation of evidence for effects on vasculopathy, fibrosis, inflammation, and endothelial cells.

Main Results:

Several drug classes show promise in addressing both vasculopathy and specific SSc pathogenic mechanisms.
Prostacyclins, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors demonstrate potential disease-modifying effects.
Current therapeutic options offer potential benefits for fibrosis, inflammation, and endothelial cell function in SSc.

Conclusions:

Vasoactive drugs targeting prostacyclin, endothelin, and phosphodiesterase pathways represent key therapeutic options for SSc.
These agents may offer disease-modifying capacity beyond symptomatic relief in systemic sclerosis.
Evidence-based recommendations are crucial for optimizing the management of SSc-related vasculopathy.